- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06604793
Creatine Supplementation in Young Healthy Adults
Effects of Equal-volume Creatine Supplementation With Different Dosing Strategies on Body Composition and Muscle Performance in Young Healthy Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Creatine is a naturally occurring compound produced in the liver and brain. Creatine can also be found in food products such as red meat and seafood or through commercially available manufactured creatine products (i.e. creatine supplementation).
Evidence-based research shows that creatine supplementation improves measures of body composition and muscle performance. However, the optimal creatine supplementation protocol to achieve these benefits is unknown.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Darren Candow
- Phone Number: 306-585-4906
- Email: Darren.Candow@uregina.ca
Study Locations
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4S 0A2
- Recruiting
- University of Regina
-
Contact:
- Darren Candow
- Phone Number: 306-585-4096
- Email: Darren.Candow@uregina.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- if you are 18-39 years of age
- if you have not been performing resistance training for at least 4 weeks prior to the start of the study.
Exclusion Criteria:
- if you are pregnant or nursing
- have taken creatine monohydrate within 30 days prior to the start of the study
- if you have pre-existing allergies to the placebo (corn-starch maltodextrin)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Creatine Bolus
(Serving 1: 5 grams of creatine monohydrate + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo in the evening) for 21 days.
|
Creatine monohydrate
|
|
Experimental: Creatine Intermittent
(Serving 1: 2.5 grams of creatine monohydrate + 5.5 grams of placebo in the morning; Serving 2: 2.5 grams of creatine monohydrate + 5.5 grams of placebo in the evening) for 21 days.
|
Creatine monohydrate
|
|
Placebo Comparator: Placebo
(Servings 1: 8 grams of placebo in the morning; Serving 2: 8 grams of placebo in the evening) for 21 days.
|
Maltodextrin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Whole-body lean mass (kg)
Time Frame: baseline, day 21
|
Bioelectrical impedance analysis
|
baseline, day 21
|
|
Strength
Time Frame: baseline, day 21
|
1-repetition maximum leg press and chest press (kg)
|
baseline, day 21
|
|
Endurance
Time Frame: baseline, day 21
|
Repetitions to fatigue for leg press and chest press (total number)
|
baseline, day 21
|
|
Hydration
Time Frame: baseline, day 21
|
Total body water (kg) using bioelectrical impedance analysis
|
baseline, day 21
|
|
Power
Time Frame: baseline, day 21
|
Vertical Jump (cm)
|
baseline, day 21
|
|
Power
Time Frame: baseline, day 21
|
Medicine Ball Throw (feet)
|
baseline, day 21
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Darren Candow, University of Regina
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 834
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Improve Muscle Performance in Young Adults
-
Uludag UniversityNot yet recruitingMuscle Strength | Physical Performance | Aerobic Capacity | Anaerobic Power | Leg Muscle Mass | Jumping Performance in Young Adults
-
Henry Ford Health SystemUniversity of Michigan; Geisinger ClinicCompletedImprove Dietary Behaviors in Young Adults 21-30 Years of AgeUnited States
-
Universidade Estadual do Norte do ParanaCompletedExercise | Performance | Young AdultsBrazil
-
Democritus University of ThraceCompletedAthletic Performance | Healthy, Young AdultsGreece
-
University of Alabama, TuscaloosaEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingSecond Language Acquisition in Healthy Young AdultsUnited States
-
Hasselt UniversityRecruitingPhysiological Responses | Functional Performance | Healthy Older Adults | Neuromuscular Function | Muscle Power | Older Adults (65 Years and Older)Belgium
-
University Medical Center GoettingenEnrolling by invitationFinancial Toxicity Related to Cancer Diagnosis and Tretment in Adolescents and Young AdultsGermany
-
Kastamonu UniversityCompletedAthletic Performance | Muscle Strength | Physical Fitness | Plyometric Exercise Adaptations | Neuromuscular Performance in AthletesTurkey (Türkiye)
-
Nantes University HospitalAGENCE NATIONALE DE RECHERCHENot yet recruitingSarcopenia | Physical Performance Decline in Older Adults | Muscle Fat Infiltration
-
University of MaiaResearch Center in Sports Sciences, Health Sciences and Human DevelopmentRecruitingFall Prevention | Functional Mobility | Balance Control in Elderly | Muscle Power PerformancePortugal
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States